{"entity":{"id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","aka":["Lancet Glob Health"],"tldr":"The Lancet's open-access global-health journal: where the numbers on cancer burden, survival gaps and treatment access in low- and middle-income countries are published.","summary":"Fully open access. Carries GLOBOCAN-based incidence and mortality analyses, the CONCORD cancer-survival programme, cervical-cancer elimination modelling and costing studies for scaling radiotherapy and chemotherapy access. Essential reading for anyone working on the 70 percent of cancer deaths that occur outside high-income countries.","asOf":"2026-09-09","links":[{"label":"Cancer collection","url":"https://www.thelancet.com/journals/langlo/collections"}],"tags":[],"related":["globocan"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mortality","radiotherapy","chemotherapy-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/langlo/home","issn":"2214-109X","scope":"global health","access":"open-access","founded":2013,"matchNames":["The Lancet Global Health","Lancet Global Health","Lancet Glob Health"]},"route":"/journals/lancet-global-health/","neighbours":{"collection":[{"id":"globocan","kind":"collection","name":"GLOBOCAN / Global Cancer Observatory","route":"/collections/globocan/"}],"term":[{"id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/"},{"id":"mortality","kind":"term","name":"Mortality","route":"/terms/mortality/"},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/"}],"person":[{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/"}],"paper":[{"id":"paper-patil-lancet-glob-health","kind":"paper","name":"Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-patil-lancet-glob-health/"}]}}